FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808568355> ?p ?o ?g. }

• W2808568355 endingPage "1977" @default.
• W2808568355 startingPage "1965" @default.
• W2808568355 abstract "To determine the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI 36/9.6, 36/7.2, 18/9.6, 9/9.6 µg) using innovative co-suspension delivery technology, compared with glycopyrrolate (GP) MDI 36 µg and formoterol fumarate (FF) MDI 9.6 µg, in patients with moderate-to-severe COPD.In this Phase IIb, randomized, double-blind, balanced incomplete-block, two-period, cross-over study (NCT01349816), patients received treatment twice-daily for 7 days. The primary efficacy endpoint was forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12) on Day 7. Secondary efficacy endpoints were peak change from baseline in FEV1 through 2 hours; time to onset of action (≥10% improvement in mean FEV1); proportion of patients achieving ≥12% improvement in FEV1 on Day 1; peak change from baseline in inspiratory capacity (IC) on Days 1 and 7; change from baseline in morning pre-dose FEV1; peak change from baseline in FEV1 through 6 hours; and change from baseline in mean evening 12-hour post-dose trough FEV1 on Day 7. Safety was assessed.All 185 randomized patients received treatment. All doses of GFF MDI significantly improved the primary endpoint compared with GP MDI 36 µg (all P≤0.0137). For peak change in FEV1 and IC and time to onset of action secondary endpoints, ≥2 doses of GFF MDI demonstrated superiority to GP MDI 36 µg. No significant differences were observed between GFF MDI and FF MDI 9.6 µg for primary and secondary endpoints. The incidence of adverse events was similar between treatments.While all doses of GFF MDI were superior to GP MDI 36 µg for the primary end-point, in this study neither superiority of GFF MDI to FF MDI 9.6 µg nor a clear dose-response was observed. All treatments were well tolerated with no unexpected safety findings." @default.
• W2808568355 created "2018-06-21" @default.
• W2808568355 creator A5025257736 @default.
• W2808568355 creator A5026538145 @default.
• W2808568355 creator A5027975503 @default.
• W2808568355 creator A5064622458 @default.
• W2808568355 creator A5077419098 @default.
• W2808568355 date "2018-06-01" @default.
• W2808568355 modified "2023-09-24" @default.
• W2808568355 title "Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD" @default.
• W2808568355 cites W1480729244 @default.
• W2808568355 cites W1890874870 @default.
• W2808568355 cites W2054931962 @default.
• W2808568355 cites W2068231614 @default.
• W2808568355 cites W2079796393 @default.
• W2808568355 cites W2094052679 @default.
• W2808568355 cites W2112628693 @default.
• W2808568355 cites W2125078269 @default.
• W2808568355 cites W2135563121 @default.
• W2808568355 cites W2166432084 @default.
• W2808568355 cites W2317895461 @default.
• W2808568355 cites W2520775112 @default.
• W2808568355 cites W2558903543 @default.
• W2808568355 cites W2568255753 @default.
• W2808568355 cites W2591678263 @default.
• W2808568355 cites W2746473595 @default.
• W2808568355 cites W2761239349 @default.
• W2808568355 cites W2765538469 @default.
• W2808568355 doi "https://doi.org/10.2147/copd.s166455" @default.
• W2808568355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6016010" @default.
• W2808568355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29950826" @default.
• W2808568355 hasPublicationYear "2018" @default.
• W2808568355 type Work @default.
• W2808568355 sameAs 2808568355 @default.
• W2808568355 citedByCount "4" @default.
• W2808568355 countsByYear W28085683552020 @default.
• W2808568355 countsByYear W28085683552021 @default.
• W2808568355 crossrefType "journal-article" @default.
• W2808568355 hasAuthorship W2808568355A5025257736 @default.
• W2808568355 hasAuthorship W2808568355A5026538145 @default.
• W2808568355 hasAuthorship W2808568355A5027975503 @default.
• W2808568355 hasAuthorship W2808568355A5064622458 @default.
• W2808568355 hasAuthorship W2808568355A5077419098 @default.
• W2808568355 hasBestOaLocation W28085683551 @default.
• W2808568355 hasConcept C121332964 @default.
• W2808568355 hasConcept C126322002 @default.
• W2808568355 hasConcept C1276947 @default.
• W2808568355 hasConcept C168563851 @default.
• W2808568355 hasConcept C19720800 @default.
• W2808568355 hasConcept C203092338 @default.
• W2808568355 hasConcept C2775859210 @default.
• W2808568355 hasConcept C2776042228 @default.
• W2808568355 hasConcept C2776136866 @default.
• W2808568355 hasConcept C2776476923 @default.
• W2808568355 hasConcept C2776780178 @default.
• W2808568355 hasConcept C2778715236 @default.
• W2808568355 hasConcept C2779871671 @default.
• W2808568355 hasConcept C2780261241 @default.
• W2808568355 hasConcept C2780667556 @default.
• W2808568355 hasConcept C2909086917 @default.
• W2808568355 hasConcept C2909581452 @default.
• W2808568355 hasConcept C42219234 @default.
• W2808568355 hasConcept C46821324 @default.
• W2808568355 hasConcept C71924100 @default.
• W2808568355 hasConceptScore W2808568355C121332964 @default.
• W2808568355 hasConceptScore W2808568355C126322002 @default.
• W2808568355 hasConceptScore W2808568355C1276947 @default.
• W2808568355 hasConceptScore W2808568355C168563851 @default.
• W2808568355 hasConceptScore W2808568355C19720800 @default.
• W2808568355 hasConceptScore W2808568355C203092338 @default.
• W2808568355 hasConceptScore W2808568355C2775859210 @default.
• W2808568355 hasConceptScore W2808568355C2776042228 @default.
• W2808568355 hasConceptScore W2808568355C2776136866 @default.
• W2808568355 hasConceptScore W2808568355C2776476923 @default.
• W2808568355 hasConceptScore W2808568355C2776780178 @default.
• W2808568355 hasConceptScore W2808568355C2778715236 @default.
• W2808568355 hasConceptScore W2808568355C2779871671 @default.
• W2808568355 hasConceptScore W2808568355C2780261241 @default.
• W2808568355 hasConceptScore W2808568355C2780667556 @default.
• W2808568355 hasConceptScore W2808568355C2909086917 @default.
• W2808568355 hasConceptScore W2808568355C2909581452 @default.
• W2808568355 hasConceptScore W2808568355C42219234 @default.
• W2808568355 hasConceptScore W2808568355C46821324 @default.
• W2808568355 hasConceptScore W2808568355C71924100 @default.
• W2808568355 hasLocation W28085683551 @default.
• W2808568355 hasLocation W28085683552 @default.
• W2808568355 hasLocation W28085683553 @default.
• W2808568355 hasLocation W28085683554 @default.
• W2808568355 hasLocation W28085683555 @default.
• W2808568355 hasOpenAccess W2808568355 @default.
• W2808568355 hasPrimaryLocation W28085683551 @default.
• W2808568355 hasRelatedWork W2568255753 @default.
• W2808568355 hasRelatedWork W2808568355 @default.
• W2808568355 hasRelatedWork W2970110245 @default.
• W2808568355 hasRelatedWork W2970121662 @default.
• W2808568355 hasRelatedWork W2970814147 @default.
• W2808568355 hasRelatedWork W2999792147 @default.
• W2808568355 hasRelatedWork W3014601936 @default.

• next